Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular ...

The FDA has granted approval to nivolumab plus ipilimumab for use in unresectable or metastatic hepatocellular carcinoma.

Researchers found that statin use decreased the risk for hepatocellular carcinoma and hepatic decompensation, which is an advanced stage of liver disease. The authors found that statin use appeare ...

People with MASLD and more so with metabolic dysfunction-associated steatohepatitis (MASH) and MASLD-associated hepatic fibrosis can progress to cirrhosis and hepatocellular carcinoma and are at ...

Investigators conducted a systematic review and meta-analysis of more than 100 studies primarily from Asia, Europe, and the US to evaluate hepatocellular carcinoma outcomes on the basis of age.

9 Patients with more advanced hepatocellular carcinoma (tumors larger than those specified in the Milan criteria) have a high risk of recurrent disease after transplantation and are therefore ...

In the study titled "Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver Disease," researchers conducted a historical cohort analysis of data from the Research ...

hepatocellular carcinoma (HCC), fibrosis, LT, and liver-related deaths from 2020 to 2050 among U.S. adults 18 years and older, utilizing a model that simulates the natural history of disease ...

The analysis included 16,501 participants: 3610 statin users and 12,891 nonusers. HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for ...